Abstract
Although thiazolidinediones and magnesium supplementation improves insulin action
and increases HDL-cholesterol, the potential link between serum magnesium and thiazolidinediones
has received little attention. Focusing on the increase of serum magnesium, 63 eligible
subjects were enrolled and randomly allocated to receive either 30 mg Pioglitazone
once daily (Group A) or lifestyle intervention (Group B) during 12 weeks. Subjects
were eligible if they were glucose-intolerant, and excluded if they had high blood
pressure, diabetes or abnormal liver function tests. The personnel assessing outcomes
were blinded to group assignment. Of the 63 eligible subjects, 3 dropped out (one
in group A, and two in Group B) because they moved out of the city. So, 30 subjects
in each group, who satisfactorily completed the follow-up, were included in the analysis
of data. There were no serious adverse events or side effects due to Pioglitazone
or lifestyle intervention. At baseline, the groups did not differ significantly in
serum magnesium levels 1.73 ± 0.17 versus 1.72 ± 0.14 mg/dl, p = 0.80. Subjects who
received Pioglitazone significantly increased their serum magnesium to 1.93 ± 0.16
mg/dl whereas in the lifestyle intervention group the increase was 1.74 ± 0.25 mg/dl,
p < 0.0001. What this study showed was a significant increase in the serum magnesium
levels of glucose-intolerant subjects who received 30 mg Pioglitazone once daily.
Key words
Pioglitazone - Magnesium - Thiazolidinediones - Impaired glucose tolerance
References
guerrero_romero@hotmail.com guerrero_romero@members.nyas.org
